Medicure Inc (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, on Monday announced its financial results for the quarter ended 31 March 2019.

The company reported net revenue from the sale of AGGRASTAT (tirofiban hydrochloride) at USD4.8m in the quarter ended 31 March 2019, compared to USD6.1m for the same period in 2018.

Net loss for the quarter ended 31 March 2019 was USD2.8m, compared to net income of USD1.4m for the year-ago period.

As of 31 March 2019, the company had unrestricted cash and short-term investments totalling USD55.5 million compared to USD71.9 million as of 31 December 2018. The decrease in cash is primarily due to the investment made in Sensible Medical Innovations Ltd. and a decrease in the value of the US dollar as of 31 March 2019 compared to 31 December 2018.